

Office of Vermont Health Access Pharmacy Benefits Management Program DUR Board Meeting Agenda

January 13, 2009 6:30 – 9:00 p.m. **

1.	Executive Session Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreeme (as provided by 33 VSA § 1998(f)(2))	6:30 - 7:00 ents
2.	Introductions and Approval of DUR Board Minutes (Public Comment Prior to Board Action)	7:00 - 7:05
3.	OVHA Pharmacy Administration Updates	7:05 - 7:10
4.	Medical Director Update	7:10 - 7:15
5.	Follow-up Items from Previous Meeting No items	7:15 - 7:15
6.	Clinical Update: Drug Reviews (Public comment prior to Board action) Relistor® (methylnaltrexone) injection	7:15 – 7:20
7.	Review of Newly-Developed/Revised Clinical Coverage Criteria (Public comment prior to Board action) Anti-psychotics: Atypicals and Combinations (Seroquel XR®) Mood Stabilizers (Equetro®) Ophthalmic Antihistamines Pulmonary: Beta-Agonists: Short Acting Metered Dose Inhalers review) Pulmonary: Inhaled Glucocorticoids: Single Agent Metered Dose (QVAR® brief review)	
8.	Drug Classes – New (Public comment prior to Board action)	7:55 – 8:10

Class review documents available on OVHA web site 01/13/09 @ 12 Noon

Pancreatic EnzymesEstrogens: Vaginal

Class review documents available on OVHA web site 01/13/09 @	9 12 Noon
Anti-Diabetics Insulin	
InsulinOral	
Alpha Glucosidase Inhibitors Discouri de continutions	
Biguanides and Combinations	
• Meglitinides	
• Sulfonylureas (Second Generation)	
 Thiazolidinediones and Combinations 	
 Dipeptidyl Peptidase Inhibitors and Combinations 	
Peptide Hormones	
Cardiovascular Agents	
 Anti-Hypertensives: ACE Inhibitors and ACEI Combinations 	
 Anti-Hypertensives: Angiotensin Receptor Blockers (ARBs) at 	nd ARB
Combinations	
 Anti-Hypertensives: Beta-Blockers 	
 Anti-Hypertensives: Calcium Channel Blockers 	
 Anti-Hypertensives: Renin Inhibitors 	
Platelet Inhibitors	
10. RetroDUR	8:45 - 8:55
 Chantix[®] and Smoking Cessation Products 	
11. New Drug Product Plan Exclusions (Consent Agenda Topic)	8:55 - 8:55
12. Updated New-to-Market Drug Monitoring Log (Consent Agend	a topic) 8:55 - 8:55
13. General Announcements Selected FDA Safety Alerts Deferred to February meeting	8:55 – 8:55
Deterred to reording meeting	
14. Adjourn	9:00

8:10 - 8:45

9. Drug Classes – Annual Review (Public comment prior to Board action)